Vitamin K2 MK-7: Bone Health, Arterial Calcification, and the Evidence

Medical disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice and is not a substitute for professional medical consultation, diagnosis, or treatment. Always speak with a qualified healthcare provider before changing your diet, supplementation routine, or treatment plan. Individuals taking anticoagulant medications such as warfarin must consult their prescribing clinician before using any vitamin K supplement.

Calcium is one of the most carefully regulated minerals in human physiology, and for good reason. The body maintains circulating calcium within an extraordinarily narrow range, any surplus must be directed somewhere. Where it goes is the central question that vitamin K2 research has spent the past three decades answering. The emerging picture is that K2, particularly in its longest-acting natural form MK-7, acts as a biological traffic controller for calcium: activating proteins that pull calcium into bone matrix and simultaneously suppressing its deposition in arterial walls.

Most people are familiar with vitamin K as a coagulation factor, the K comes from the German Koagulation. What is far less understood is that the vitamin K family comprises structurally distinct molecules with meaningfully different functions, and that the form found in fermented foods and animal products operates on tissues that the leafy-green form barely reaches at all.

---

The Vitamin K Family: K1 vs K2

Vitamin K1 (phylloquinone) is synthesised by plants and found in highest concentrations in dark leafy greens, kale, spinach, and broccoli are the richest dietary sources. K1 is the dominant form in most Western diets and is preferentially used by the liver, where it drives the activation of coagulation factors II, VII, IX, and X. After serving this function, K1 is rapidly cleared from the circulation. Its half-life is measured in hours.

Vitamin K2 is a family of molecules called menaquinones, designated MK-4 through MK-13 based on the length of their side chain. They are produced by bacteria during fermentation and found in animal products where gut bacteria have contributed to tissue accumulation. The critical biological distinction between K1 and K2 is tissue distribution: K2 menaquinones are not retained exclusively in the liver. They circulate for longer and reach extrahepatic tissues (arterial walls, bone, kidneys, and the brain) where vitamin K-dependent proteins are expressed but receive essentially no K1.

This means coagulation is adequately served by dietary K1 in virtually all healthy people. But the proteins governing calcium handling in bone and vasculature are a different matter entirely, they depend on K2, and they are frequently underactivated in people eating modern Western diets.

---

MK-4 vs MK-7: Why Half-Life Matters

Within the K2 family, MK-4 and MK-7 are the most studied and the most relevant to supplementation. MK-4 is the form found in animal products such as egg yolk and chicken liver. MK-7 is the form found in natto (fermented soybeans) and is the dominant long-chain menaquinone in most commercial supplements.

The pharmacokinetic differences are substantial. MK-4 has a half-life of approximately 1–2 hours in human circulation, requiring frequent dosing or very high single doses to maintain sustained tissue levels. MK-7 has a half-life of approximately 72 hours, three full days, which means a once-daily dose maintains consistent circulating levels across the day-night cycle without the peaks and troughs seen with MK-4.

This sustained bioavailability matters for the extrahepatic proteins that K2 is meant to activate. Osteocalcin in bone and Matrix Gla Protein in arterial walls require continuous K2 availability to remain in their carboxylated, active state. A supplement that spikes and clears within a few hours provides only a brief window of activation, leaving these proteins undercarboxylated for the remainder of the day. MK-7's extended half-life provides more continuous coverage at lower absolute doses, clinical trials demonstrating bone effects have used doses as low as 90–180 mcg/day of MK-7, whereas MK-4 trials have typically used 15,000–45,000 mcg/day (15–45 mg) to achieve comparable outcomes.

---

The Two Proteins That Explain Everything

The functional importance of K2 converges on two vitamin K-dependent proteins outside the coagulation cascade. Understanding these proteins explains both the bone effects and the cardiovascular effects documented in the literature.

Osteocalcin

Osteocalcin is produced by osteoblasts, the bone-forming cells, and is the second most abundant protein in bone after collagen. Its role is to bind calcium and hydroxyapatite and anchor them within the collagen matrix, contributing to the mineralisation and structural integrity of bone. Osteocalcin contains three glutamate residues that must be carboxylated to gamma-carboxyglutamate (Gla) by a vitamin K-dependent enzyme, gamma-glutamyl carboxylase, before the protein can bind calcium effectively.

When vitamin K2 is insufficient, osteocalcin is synthesised but remains in its undercarboxylated form (ucOC). Undercarboxylated osteocalcin is now routinely measured as a functional marker of K2 status, not a direct measure of K2 in the blood, but a readout of whether K2-dependent carboxylation is occurring adequately in bone tissue. Elevated ucOC signals that the cellular machinery is present but the cofactor is limiting.

Osteocalcin also has a secondary, metabolically significant function: its undercarboxylated form acts as a hormone signalling to adipose tissue and pancreatic beta cells, influencing insulin sensitivity and energy metabolism. This adds a dimension to K2 deficiency beyond bone quality, though the full clinical implications are still being characterised.

Matrix Gla Protein (MGP)

Matrix Gla Protein is the most potent known inhibitor of soft-tissue calcification. It is expressed at highest levels in vascular smooth muscle cells and cartilage, and it functions by binding calcium ions and calcium crystals in arterial walls, preventing their deposition. Like osteocalcin, MGP requires K2-dependent carboxylation to be active, uncarboxylated MGP (ucMGP) is non-functional and, critically, is itself deposited at calcification sites where it can be directly measured.

High circulating ucMGP is now used in clinical research as a marker of vascular vitamin K insufficiency. Patients on long-term warfarin therapy, which blocks vitamin K recycling, have dramatically elevated ucMGP and correspondingly accelerated arterial calcification. This pharmacological inverse of K2 sufficiency provided early and compelling evidence that the K2/MGP axis is clinically real.

The elegant logic of K2 is this: bone and arteries compete for the same calcium load, and K2-dependent proteins determine the winner. Activate osteocalcin and MGP adequately, and calcium enters bone matrix while arterial walls remain clear. Deplete K2, and both proteins fail, bone loses density and arteries calcify simultaneously, which is precisely the pattern observed when postmenopausal osteoporosis and cardiovascular disease co-occur.

---

Bone Evidence: The ECHOSA Trial and Beyond

The most rigorous intervention evidence for K2 and bone comes from the ECHOSA trial (Knapen et al., 2013), published in Osteoporosis International. This was a three-year, double-blind, randomised controlled trial in 244 healthy postmenopausal women, a population selected because declining oestrogen accelerates bone resorption and makes bone loss measurable within a clinically reasonable timeframe.

Participants received either 180 mcg/day of MK-7 (as MenaQ7, a natto-derived form) or placebo. At the end of three years:

• The MK-7 group maintained femoral neck bone strength indices that declined in the placebo group.
• Lumbar spine bone mineral content and density showed less decline in the MK-7 group.
• Circulating ucOC decreased significantly in the MK-7 group, confirming that the dose was biologically active and reaching bone tissue.
• Stiffness index, a measure of bone mechanical quality derived from quantitative ultrasound, was significantly higher in the MK-7 group, with the difference becoming statistically meaningful at 36 months.

The ECHOSA trial is notable for several reasons. The dose (180 mcg/day) is low and clinically achievable through supplementation. The duration (three years) is sufficient to detect meaningful structural changes. And the outcome, maintenance of bone strength rather than absolute improvement, reflects the realistic goal of nutritional intervention in postmenopausal bone: slowing the trajectory of loss rather than reversing years of accumulated deficit.

The Rotterdam Study, a large Dutch prospective cohort published by Geleijnse and colleagues in the Journal of Nutrition, also provided dietary K2 data relevant to bone. Higher dietary K2 intake, principally from cheese, was associated with significantly lower risk of fractures, though the observational design limits causal inference and cannot rule out confounding from overall dietary quality.

The combination of vitamin K2 and vitamin D3 has received substantial attention because both nutrients participate in calcium metabolism at different steps. D3 drives intestinal calcium absorption and raises serum calcium availability. K2 then directs that calcium toward bone via osteocalcin activation and away from arteries via MGP activation. Several combination trials have shown superior bone density outcomes for the K2 plus D3 pairing versus D3 alone, and the mechanistic rationale for combining them is strong. Taking D3 without adequate K2 potentially increases calcium availability without ensuring its appropriate distribution, a consideration that has become more prominent as high-dose D3 supplementation has become widespread. The role of collagen and bone matrix proteins in supporting the structural scaffold that mineralisation depends on is explored in our collagen peptides nutrition evidence and bone broth nutritional analysis articles.

---

Cardiovascular Evidence: The Rotterdam Study and Arterial Calcification Data

The cardiovascular evidence for dietary K2 is anchored in the Rotterdam Study (Geleijnse et al., 2004), published in the Journal of Nutrition. In 4,807 Dutch adults followed for a mean of 7–10 years, dietary K2 intake was assessed by food-frequency questionnaire and divided into tertiles.

The findings were striking:

• Those in the highest tertile of dietary K2 intake had a 57% lower risk of aortic calcification compared with those in the lowest tertile.
• The highest K2 tertile also had a 52% lower risk of cardiovascular mortality and a 41% lower risk of coronary heart disease compared with the lowest tertile.
• Vitamin K1 showed no such associations, the protective effect was specific to K2 menaquinones, consistent with the tissue distribution data showing K1 does not reach vascular smooth muscle in meaningful quantities.

The primary dietary K2 source in this Dutch population was cheese, a traditional fermented food containing MK-4 and longer-chain menaquinones contributed by bacterial cultures during aging. This is not a trivial point: the Rotterdam findings are not driven by an unusual dietary pattern but by a food (aged cheese) that remains common in European diets and is entirely compatible with normal eating.

Jie et al. (1996) examined coronary artery calcification and vitamin K status directly, finding that patients with severe coronary calcification had significantly lower K status compared with non-calcified controls, and that bone loss and arterial calcification tended to co-occur, consistent with the dual-protein framework described above. While earlier and smaller than the Rotterdam analysis, this work pointed to the same mechanistic axis: K2-dependent MGP insufficiency as a driver of vascular calcium deposition.

The research community working on bioactive cardiovascular compounds, including those cataloguing relevant evidence at bioactive cardiovascular compound research at RetaLABS, has highlighted the K2/MGP axis as one of the more mechanistically coherent nutritional strategies for vascular health, with a plausible pathway from nutrient to protein function to measurable tissue outcome.

---

Why Deficiency Is Common

Despite K2's importance, dietary K2 insufficiency is widespread in Western populations. Several converging factors explain this.

Low fermented food intake: Natto, the richest dietary source of MK-7, is a staple in certain Japanese regions but essentially absent from Western diets. Aged cheeses provide meaningful MK-4 and some MK-7, but consumption patterns vary enormously. Most people eating a standard Western diet get abundant K1 from vegetables but negligible K2 from fermented or aged animal foods.

Fat-solubility: Vitamin K2 is fat-soluble and requires dietary fat for intestinal absorption. Low-fat dietary patterns that restrict cheese, egg yolk, and animal fats reduce K2 intake by both eliminating the food source and impairing absorption of what little K2 is present.

Antibiotic use and gut microbiome disruption: Some K2 menaquinones are synthesised by intestinal bacteria and contribute to systemic K2 levels. Antibiotic courses that broadly suppress gut bacteria temporarily reduce this endogenous contribution. Chronic gut dysbiosis, with reduced diversity and reduced populations of K2-producing bacteria, likely lowers the microbial contribution to K2 status over the long term.

Age-related changes: Intestinal absorption efficiency declines with age, and older adults are more likely to be on medications (including proton pump inhibitors) that alter the gut environment. Postmenopausal women are the most studied population for K2 deficiency effects precisely because they are both at highest risk for bone loss and frequently eating low-fat diets that inadvertently restrict K2 intake.

---

Food Sources

For those wanting to address K2 status through diet:

• Natto is the most concentrated food source by a considerable margin, with approximately 1,000 mcg of MK-7 per 100 g. A single small serving (40–50 g) provides a dose consistent with supplementation trials. The taste and texture are polarising and natto is not widely available outside Japanese grocery stores.
• Gouda and other aged hard cheeses provide approximately 75 mcg of mixed MK-4 and longer-chain menaquinones per 100 g. Daily cheese consumption at typical quantities (30–50 g) contributes a modest but meaningful amount, which likely explains part of the Rotterdam finding.
• Egg yolks contain MK-4 in amounts that vary with the animal's diet. Pasture-raised hens foraging on greens and insects produce yolks with higher K2 content than conventionally fed birds.
• Chicken liver is one of the higher animal-food sources of MK-4.
• Butter and cream from grass-fed animals contain modest K2, predominantly as MK-4.

No plant food other than natto provides meaningful K2. This is relevant for those following vegan or plant-based diets, where MK-7 supplementation derived from natto is the practical solution.

---

Dosing, Safety, and the Warfarin Interaction

For general health purposes, 90–200 mcg/day of MK-7 represents the evidence-supported range. The 180 mcg dose used in the ECHOSA trial is a reasonable reference point for bone-focused supplementation. Some cardiovascular protocols use doses at the higher end of this range, though controlled trial data above 200 mcg/day are more limited.

MK-7 is considered extremely safe at these doses. No tolerable upper limit has been established by regulatory bodies, and toxicity from food or supplemental K2 has not been documented. Because K2 does not stimulate coagulation with the same potency as K1 at physiological doses, it lacks the haemostatic risks sometimes raised in the context of vitamin K generally.

The critical exception is anticoagulation therapy. Warfarin and related vitamin K antagonists work by blocking vitamin K recycling, and any consistent K vitamin intake, including K2, can affect INR stability and anticoagulation control. This is not an absolute contraindication, but it is an absolute requirement for prescriber involvement before any change in K intake. Patients on warfarin should not begin or discontinue K2 supplements without INR monitoring and clinician guidance.

MK-7 is ideally taken with a meal containing fat to support absorption. The long half-life means timing within the day is not critical, but consistency, taking it daily rather than sporadically, matters for maintaining the sustained circulating levels that drive ongoing protein carboxylation.

---

Practical Summary

Vitamin K2 MK-7 occupies an unusual position in nutritional science: the evidence is mechanistically coherent (two well-characterised proteins, one regulatory nutrient), the clinical trial data are encouraging (ECHOSA for bone, Rotterdam for cardiovascular outcomes), the doses required are low, and the safety profile is excellent. Yet awareness remains limited, and dietary K2 intake among Western populations is systematically inadequate.

The case for attention to K2 status is strongest in postmenopausal women, older adults with cardiovascular risk factors, and anyone following a dietary pattern that restricts fermented foods and animal fats. For the broader population, the combination of K2 MK-7 and vitamin D3 represents one of the more evidence-grounded nutritional pairings available, D3 raising calcium availability, K2 ensuring it goes where the body needs it most.

Those interested in the broader landscape of evidence-based nutritional compounds and how K2 fits alongside other longevity-adjacent nutrients can explore additional perspectives in our NMN vs NR nutrition angle.

The gap between what we know about K2 and how widely that knowledge has translated into dietary practice remains substantial. The Rotterdam Study was published in 2004. The ECHOSA trial reported in 2013. The mechanistic case has been solid for longer than either. At 90–200 mcg/day of MK-7, the intervention required to address deficiency is modest. The biology behind it is not.